A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable ...
When you think of lung cancer treatment, what comes to mind—chemotherapy, radiation, surgery? While these can be crucial, ...
What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
For the first time, the National Institute for Health and Care Excellence has recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce ...
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE ...
Research shows regular physical activity can significantly improve quality of life for lung cancer patients. This includes ...
Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...